HCA Healthcare, Inc. (HCA) Cash Flow Statement

The wide quarterly swings in OCF/NI, ranging from 1.03 to 2.77, appear driven by working capital fluctuations, particularly in receivables and payables, rather than fundamental earnings quality issues. The 2025Q3 spike to 2.69 likely reflects a temporary release of working capital, while the 2026Q1 dip to 1.24 suggests a build-up in receivables. Investors should monitor the cumulative conversion over several quarters to assess the true quality of earnings, as the gap between net income and operating cash flow is not consistently widening.

The FCF trajectory shows a clear pattern of volatility, with strong quarters in 2025Q2 and Q3 (16.3% margin) followed by a sharp contraction in 2026Q1 (3.6%). The 2026Q2 improvement to 5.5% indicates a partial rebound, but the level remains well below the 2025 average, suggesting that working capital swings are heavily influencing reported FCF. Compared to net income, FCF has been consistently lower on a cumulative basis, reflecting the capital-intensive nature of the business and the impact of working capital timing.

The CapEx/Revenue ratio has hovered around 6-7%, with the most recent quarter at 6.1%, suggesting a disciplined approach to capital spending. This level appears consistent with maintenance needs plus moderate growth investments, particularly in outpatient facilities and freestanding emergency rooms. The stability of this ratio, despite revenue growth, implies that HCA is not significantly increasing its capital intensity, which may support future FCF generation if revenue continues to expand.

The extreme volatility in working capital changes, with swings of over $4B between quarters, appears to be a primary driver of the fluctuating OCF/NI ratios. The positive $2.3B in 2025Q3 likely reflects strong collections, while the negative $1.7B in 2025Q1 suggests a build-up in receivables or a drawdown in payables. This pattern may indicate that HCA's cash conversion cycle is sensitive to payer mix and claim processing times, which investors should monitor for any structural shifts.

HCA's capital deployment strategy remains heavily skewed toward share repurchases, with buybacks consistently exceeding FCF in most quarters. In 2026Q2, buybacks were nearly double FCF, suggesting reliance on cash reserves or debt to fund the program. This aggressive approach has supported EPS growth, as noted in the income statement analysis, but may increase financial leverage if sustained. Dividends remain modest and stable, while acquisition activity is relatively small, indicating a clear priority on returning capital to shareholders.

The cumulative gap between operating cash flow and net income is substantial, with OCF exceeding NI by $11.7B over the period. This suggests that non-cash charges like depreciation and amortization, which totaled approximately $8.7B, are a major contributor, but even after accounting for that, there is a positive gap. This may indicate conservative revenue recognition or favorable working capital management, but investors should note that the gap is not consistent quarter-to-quarter, reflecting the lumpy nature of supplemental payments and other timing items.